OncoMatch/Clinical Trials/NCT04883437
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Is NCT04883437 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Obinutuzumab and Acalabrutinib for grade 1 follicular lymphoma.
Treatment: Acalabrutinib · Obinutuzumab — This phase II trial studies the effect of acalabrutinib and obinutuzumab in treating patients with follicular lymphoma or other indolent non-Hodgkin lymphoma for which the patient has not received treatment in the past (previously untreated). Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Giving acalabrutinib and obinutuzumab may kill more cancer cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: lymphoma-directed therapy
Exception: anti-microbial therapy for infection-associated marginal zone lymphoma such as hepatitis C or H pylori
Prior receipt of lymphoma-directed therapy or prior antibody-based therapy (except for anti-microbial therapy for infection-associated marginal zone lymphoma such as hepatitis C or H pylori)
Cannot have received: antibody-based therapy
Exception: anti-microbial therapy for infection-associated marginal zone lymphoma such as hepatitis C or H pylori
Prior receipt of lymphoma-directed therapy or prior antibody-based therapy (except for anti-microbial therapy for infection-associated marginal zone lymphoma such as hepatitis C or H pylori)
Lab requirements
Blood counts
ANC < 1,000/mcL; Platelet count < 50,000/mcL (unless felt to be related to underlying disease)
Kidney function
Creatinine clearance <= 40 mL/min/1.73m^2
Liver function
Total bilirubin >= 1.5 x ULN (isolated bilirubin > 1.5 x ULN is permitted if direct proportion is < 35%); AST/ALT > 2.5 x ULN
Cardiac function
Clinically significant cardiovascular disease such as symptomatic ventricular arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
ANC < 1,000/mcL; Platelet count < 50,000/mcL (Unless felt to be related to underlying disease); Total bilirubin >= 1.5 x ULN (Isolated bilirubin > 1.5 x ULN is permitted if the direct proportion is < 35%); AST/ALT > 2.5 x ULN; Creatinine clearance <= 40 mL/min/1.73m^2; Clinically significant cardiovascular disease such as symptomatic ventricular arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any class 3 or 4 cardiac disease as defined by the New York Heart Association Functional Classification
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Emory University Hospital/Winship Cancer Institute · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify